文献速递消化、代谢与肾脏急症

超低剂量纳洛酮联合吗啡与单用吗啡治疗肾绞痛的镇痛效果比较

Does co-treatment with ultra-low-dose naloxone and morphine provide better analgesia in renal colic patients?
PubMed 文献 · Am J Emerg Med · 2018-08-16
一句话结论双盲临床试验显示,超低剂量静脉纳洛酮联合吗啡与单用吗啡相比,未能为肾绞痛患者提供更好的镇痛和镇静状态。

该双盲临床试验纳入150例34至60岁因肾绞痛就诊于急诊科的患者,随机分为超低剂量静脉纳洛酮联合静脉吗啡组或吗啡加安慰剂组。在入急诊时及开始治疗后20、40、60、120、180分钟评估疼痛、镇静和恶心程度,采用数字评定量表(NRS)评估疼痛和恶心,Ramsay镇静量表(RSS)评估镇静。广义估计方程模型显示,纳洛酮组疼痛评分较吗啡组降低但无统计学显著差异(系数=-0.68;95%CI:-1.24至-0.11,Wald X2(1)=5.41,p=0.02)。在T5和T6时点,纳洛酮组与吗啡组RSS评分等于3者分别为1.5% vs 20%和1.5% vs 16.9%(p=0.001和p=0.004)。结论认为,与单用静脉吗啡相比,超低剂量纳洛酮联合吗啡未能为肾绞痛患者提供更好的镇痛和镇静/激越状态。

要点

  • 在150例34至60岁肾绞痛急诊患者中,超低剂量静脉纳洛酮联合静脉吗啡组疼痛评分较单用吗啡组降低但无统计学显著差异(系数=-0.68;95%CI:-1.24至-0.11,p=0.02)。
  • T1至T4时点,纳洛酮联合吗啡组与单用吗啡组的镇静评分无统计学显著差异。
  • T5时点,纳洛酮组1.5% vs 吗啡组20%的患者RSS评分等于3(p=0.001)。
  • T6时点,纳洛酮组1.5% vs 吗啡组16.9%的患者RSS评分等于3(p=0.004)。
  • 作者结论认为,超低剂量纳洛酮联合吗啡未能为肾绞痛患者提供更好的镇痛和镇静/激越状态。

适用人群与场景

  • 因肾绞痛就诊于急诊科、年龄34至60岁的患者。

研究设计与关键结果

  • 研究类型为双盲临床试验,纳入150例因肾绞痛就诊于急诊科的患者,随机分为超低剂量静脉纳洛酮联合静脉吗啡组或吗啡加安慰剂组。
  • 在入急诊时(T1)及开始治疗后20(T2)、40(T3)、60(T4)、120(T5)、180(T6)分钟评估疼痛、镇静和恶心,采用NRS评估疼痛和恶心,RSS评估镇静。
  • 广义估计方程模型显示,纳洛酮组疼痛评分较吗啡组降低但无统计学显著差异(系数=-0.68;95%CI:-1.24至-0.11,Wald X2(1)=5.41,p=0.02)。
  • T1至T4时点,纳洛酮联合吗啡组与单用吗啡组的镇静评分无统计学显著差异。
  • T5时点,纳洛酮组1.5% vs 吗啡组20%的患者RSS评分等于3(p=0.001)。
  • T6时点,纳洛酮组1.5% vs 吗啡组16.9%的患者RSS评分等于3(p=0.004)。

证据类型、等级与局限

  • 证据类型:双盲临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,与单用静脉吗啡相比,超低剂量纳洛酮联合吗啡未能为肾绞痛患者提供更好的镇痛和镇静/激越状态。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: This study attempted to evaluate the efficacy of ultra-low-dose intravenous (IV) naloxone combined with IV morphine, as compared to IV morphine alone, in terms of reducing pain and morphine-induced side effects in patients with renal colic.

METHODS: In this double-blind clinical trial, 150 patients aged 34 to 60 years old who presented to the emergency department (ED) with renal colic were randomly allocated to either an intervention group that received ultra-low-dose IV naloxone combined with IV morphine or to a control group that received morphine plus a placebo. The severity of pain, sedation, and nausea were assessed and recorded for all patients at entrance to the ED (T1), then at 20 (T2), 40 (T3), 60 (T4), 120 (T5), and 180 (T6) minutes after starting treatment. The Numeric Rating Scale (NRS) was used for the assessment of pain and nausea intensities, and the Ramsay Sedation Scale (RSS) was used to assess sedation.

RESULTS: A GEE model revealed that patients in the naloxone group had non-significantly reduced pain scores compared to those in the morphine group (coefficient = -0.68; 95% CI: -1.24 to -0.11, Wald X2 (1) = 5.41, p = 0.02). The sedation outcome demonstrated no statistically significant differences at T1 to T4 among patients with renal colic compared to the ones who only received morphine. At T5 and T6, 1.5% vs. 20% and 1.5% vs. 16.9% of subjects from the naloxone group versus the morphine group obtained RSS scores equal to 3, respectively (p = 0.001 and p = 0.004, respectively).

CONCLUSIONS: Compared to patients who only received IV morphine, co-treatment of ultra-low-dose naloxone with morphine could not provide better analgesia and sedation/agitation states in renal colic patients.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Hosseininejad SM, Mohammadian Amiri M, Bozorgi F, et al. Does co-treatment with ultra-low-dose naloxone and morphine provide better analgesia in renal colic patients? Am J Emerg Med. 2018. PMID: 30121157. doi:10.1016/j.ajem.2018.08.038

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。